Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Medicare Advisers Endorse Patient Reported Outcomes For CAR-T With Caveats

Executive Summary

Medicare Evidence Development and Coverage Advisory Committee votes that four existing tools are valid and could be “generalizable” to Medicare beneficiaries.
Advertisement

Related Content

Drug Pricing Critic Peter Bach Named Chair Of Medicare Advisory Panel
CAR-T Patients’ Ongoing Needs After Treatment Highlighted At MedCAC Meeting
CAR-T Reimbursement Threatened By Medicare Coverage Analysis, Manufacturers Say
CAR-T Therapy In Medicare: National Coverage Policy Could Come In 2019
Oncology PROs: Limited Use Due To Small Trials, Fast Drug Development

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS123756

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel